| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcce39a20bef16c3f04497659caba40f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2018-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b39d6949195e761d95cd7f0cb640905
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f28e2015a923c3465eaa9cd28d8cd93 |
| publicationDate |
2020-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112020004225-A2 |
| titleOfInvention |
anti-egfr (adc) antibody drug conjugates and uses thereof |
| abstract |
the present disclosure provides drug-antibody conjugates (adcs) comprising a cytostatic or cytotoxic agent attached to an anti-egfr antibody by means of a binder, compositions comprising adcs, methods of manufacturing adcs and methods for treating a cancer that comprise administering addcs to a subject who has cancer. the present disclosure provides adcs that specifically bind egfr and, in particular, human egfr (hegfr). the anti-egfr ab described in this document comprises an s239c mutation in a heavy chain constant region, where the numbering is in accordance with kabat. |
| priorityDate |
2017-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |